Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

AsclepiX Therapeutics

Request full access

Developing therapies to treat ocular diseases

Bethesda, United StatesFounded 2011Biotech & Life Sciences

About AsclepiX Therapeutics

AsclepiX Therapeutics is a biotechnology company focused on developing innovative peptide-based therapies for the treatment of retinal vascular diseases and cancer. The company's lead candidate, AXT107, is a synthetic peptide derived from collagen IV protein sequences. AXT107 works by inhibiting the pro-angiogenic VEGFR2 receptor and activating the vessel-stabilizing Tie2 receptor, addressing two key pathways in retinal vascular disease treatment. AsclepiX was founded by researchers from Johns Hopkins University School of Medicine and has since grown under the leadership of experienced biomedical and pharmaceutical executives. The company operates in the biopharmaceutical market, primarily serving patients with unmet medical needs in ocular diseases and oncology. AsclepiX's business model involves the rapid clinical development and commercialization of its novel therapeutics. Revenue is generated through the successful development and potential future sales of its drug candidates.

Source: Dealroom company data

At a glance

Status
Operational
Employees
5
Open positions
None listed
Dealroom signal
62.8/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jul 2023 $10M $175M Rapha Capital Management · Hibiscus BioVentures · Perceptive Advisors ↗
SERIES AOther financing Jun 2020 $35M $140M Rapha Capital Management · Perceptive Advisors —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

AsclepiX Therapeutics website traffic

Latest recorded traffic for AsclepiX Therapeutics is 430 monthly website visits, down 64.2% over the last three months. AsclepiX Therapeutics's team declined 16.7% over the past year.

Latest monthly visits430 3-month web change-64.2% 1-year team growth-16.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

AsclepiX Therapeutics in the Bethesda ecosystem

Live from Dealroom

The AsclepiX Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Other known investors1 additional known investor

  • Johns Hopkins University
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about AsclepiX Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AsclepiX Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.